Evidence map›Paper›PMID 32318042›Full record

ArticleFrontiers in microbiology2020

Chemical, Metabolic, and Cellular Characterization of a FtsZ Inhibitor Effective Against

Laurent R Chiarelli, Viola Camilla Scoffone, Gabriele Trespidi, Giulia Barbieri, Olga Riabova, Natalia Monakhova, Alessio Porta, Giulia Manina, Giovanna Riccardi, Vadim Makarov and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Antistaphylococcal Activity of the FtsZ Inhibitor C109.Pathogens (Basel, Switzerland) · 2021
    Article
  4. Molecular Characterization of theAntibiotics (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Laurent R ChiarelliLaboratory of Molecular Microbiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
Viola Camilla ScoffoneLaboratory of Molecular Microbiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
Gabriele TrespidiLaboratory of Molecular Microbiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
Giulia BarbieriLaboratory of Molecular Microbiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
Olga RiabovaFederal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences, Moscow, Russia.
Natalia MonakhovaFederal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences, Moscow, Russia.
Alessio PortaOrganic Chemistry Section, Department of Chemistry, University of Pavia, Pavia, Italy.
Giulia ManinaMicrobial Individuality and Infection Group, Cell Biology and Infection Department, Institut Pasteur, Paris, France.
Giovanna RiccardiLaboratory of Molecular Microbiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
Vadim MakarovFederal Research Centre "Fundamentals of Biotechnology" of the Russian Academy of Sciences, Moscow, Russia.
Silvia BuroniLaboratory of Molecular Microbiology, Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
University of Pavia · ITFederal Center Research Fundamentals of Biotechnology · RUInstitut Pasteur · FRRussian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need for new antimicrobials to treat the opportunistic Gram-negative

Indexed as

Burkholderia cenocepaciacell divisioncystic fibrosisdrug resistancenew antimicrobials

Identifiers

PMID32318042
PMCPMC7154053
OpenAlexW3016249575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.